↓ Skip to main content

Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study

Overview of attention for article published in Frontiers in endocrinology, May 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
1 X user
f1000
1 research highlight platform

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study
Published in
Frontiers in endocrinology, May 2022
DOI 10.3389/fendo.2022.871009
Pubmed ID
Authors

Monika Sarnat-Kucharczyk, Maria Świerkot, Gabriela Handzlik, Grażyna Kulawik, Krystyna Jagoda, Iga Grochoła-Małecka, Joanna Fryżewska, Ewa Mrukwa-Kominek, Jerzy Chudek

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 17%
Lecturer 1 17%
Other 1 17%
Unknown 3 50%
Readers by discipline Count As %
Environmental Science 1 17%
Business, Management and Accounting 1 17%
Neuroscience 1 17%
Medicine and Dentistry 1 17%
Unknown 2 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2022.
All research outputs
#17,287,336
of 26,169,168 outputs
Outputs from Frontiers in endocrinology
#4,595
of 13,372 outputs
Outputs of similar age
#253,872
of 450,275 outputs
Outputs of similar age from Frontiers in endocrinology
#218
of 765 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. This one is in the 31st percentile – i.e., 31% of other outputs scored the same or lower than it.
So far Altmetric has tracked 13,372 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 60% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,275 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 765 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.